(0.79%) 5 168.18 points
(0.25%) 38 771 points
(0.93%) 16 306 points
(0.56%) $78.55
(2.43%) $2.19
(1.10%) $2 334.10
(3.69%) $27.68
(0.04%) $965.65
(-0.01%) $0.929
(-0.36%) $10.84
(-0.10%) $0.796
(-0.12%) $91.34
-0.93% $ 1.070
Live Chart Being Loaded With Signals
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 targeting the chemokine receptor CCR8...
Stats | |
---|---|
Volumen de hoy | 1.46M |
Volumen promedio | 798 146 |
Capitalización de mercado | 65.08M |
EPS | $0 ( 2024-05-02 ) |
Próxima fecha de ganancias | ( $0 ) 2024-07-31 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.686 |
ATR14 | $0.0570 (5.33%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-09-08 | Sigal Charles Elliott | Sell | 45 453 | Common Stock |
2023-09-08 | Sigal Charles Elliott | Sell | 113 636 | Stock Option (Right to Buy) |
2023-09-08 | Adams Chandra | Sell | 23 884 | Common Stock |
2023-09-08 | Adams Chandra | Sell | 50 000 | Stock Option (Right to Buy) |
2023-09-08 | Rath Henry C. | Sell | 44 971 | Common Stock |
INSIDER POWER |
---|
-73.84 |
Last 94 transactions |
Buy: 4 462 585 | Sell: 5 534 482 |
Volumen Correlación
Surface Oncology Inc Correlación
10 Correlaciones Más Positivas | |
---|---|
TETC | 0.936 |
SGEN | 0.935 |
SGIIU | 0.935 |
VLAT | 0.935 |
ADAL | 0.934 |
MSDAU | 0.933 |
BRIV | 0.932 |
VMGA | 0.93 |
APXI | 0.929 |
AFAR | 0.928 |
10 Correlaciones Más Negativas | |
---|---|
MSEX | -0.948 |
GPRO | -0.945 |
RVSB | -0.941 |
JJSF | -0.941 |
IMBI | -0.939 |
MKTW | -0.939 |
AVXL | -0.938 |
TBLT | -0.936 |
TSBK | -0.933 |
NYMT | -0.931 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Surface Oncology Inc Correlación - Moneda/Commodity
Surface Oncology Inc Finanzas
Annual | 2022 |
Ingresos: | $30.00M |
Beneficio Bruto: | $30.00M (100.00 %) |
EPS: | $-1.170 |
FY | 2022 |
Ingresos: | $30.00M |
Beneficio Bruto: | $30.00M (100.00 %) |
EPS: | $-1.170 |
FY | 2021 |
Ingresos: | $2.69M |
Beneficio Bruto: | $0.00 (0.00 %) |
EPS: | $-1.735 |
FY | 2020 |
Ingresos: | $126.16M |
Beneficio Bruto: | $0.00 (0.00 %) |
EPS: | $1.670 |
Financial Reports:
No articles found.
Surface Oncology Inc
Surface Oncology, Inc., a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 targeting the chemokine receptor CCR8. Surface Oncology, Inc. has a license agreement with GlaxoSmithKline Intellectual Property (No. 4) Limited to develop, manufacture, and commercialize antibodies that targets SRF813; and license agreement with Vaccinex, Inc. to develop, manufacture, and commercialize antibodies, which targets SRF114. The company was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico